Abstract
Structural and morphological changes in limbic brain regions are associated with depression, chronic stress and antidepressant treatment, and increasing evidence supports the hypothesis that dysregulation of cell proliferation contributes to these effects. We review the morphological alterations observed in two brain regions implicated in mood disorders, the prefrontal cortex and hippocampus, and discuss the similarities and differences of the cellular consequences of chronic stress. We briefly discuss the proposed mechanisms implicated in neuroplasticity impairments that result from stress and that contribute to mood disorders, with a particular interest in adult neurogenesis and gliogenesis. This information has contributed to novel antidepressant medication development that utilizes adult neurogenesis and gliogenesis as preclinical cellular markers for predicting antidepressant properties of novel compounds.
Keywords: major depressive disorder, selective serotonin reuptake inhibitors, Hippocampal Volume, vascular endothelial growth factor, Glucocorticoids
CNS & Neurological Disorders - Drug Targets
Title: Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant Treatment
Volume: 6 Issue: 5
Author(s): Mounira Banasr and Ronald S. Duman
Affiliation:
Keywords: major depressive disorder, selective serotonin reuptake inhibitors, Hippocampal Volume, vascular endothelial growth factor, Glucocorticoids
Abstract: Structural and morphological changes in limbic brain regions are associated with depression, chronic stress and antidepressant treatment, and increasing evidence supports the hypothesis that dysregulation of cell proliferation contributes to these effects. We review the morphological alterations observed in two brain regions implicated in mood disorders, the prefrontal cortex and hippocampus, and discuss the similarities and differences of the cellular consequences of chronic stress. We briefly discuss the proposed mechanisms implicated in neuroplasticity impairments that result from stress and that contribute to mood disorders, with a particular interest in adult neurogenesis and gliogenesis. This information has contributed to novel antidepressant medication development that utilizes adult neurogenesis and gliogenesis as preclinical cellular markers for predicting antidepressant properties of novel compounds.
Export Options
About this article
Cite this article as:
Banasr Mounira and Duman S. Ronald, Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant Treatment, CNS & Neurological Disorders - Drug Targets 2007; 6 (5) . https://dx.doi.org/10.2174/187152707783220929
DOI https://dx.doi.org/10.2174/187152707783220929 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews Docking of Natural Products against Neurodegenerative Diseases: General Concepts
Combinatorial Chemistry & High Throughput Screening O-Arylation of Iodophenols with 2-Fluorobenzaldehyde Under Microwave Conditions
Letters in Drug Design & Discovery Possible Neuroprotective Strategies in ALS
Current Neuropharmacology Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Meet Our Associate Editor
Current Molecular Medicine Stem Cell-Derived Oligodendroglial Cells for Therapy in Neurological Diseases
Current Stem Cell Research & Therapy Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design Topiramate: Its Pharmacological Properties and Therapeutic Efficacy in Epilepsy
Mini-Reviews in Medicinal Chemistry New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Update on the Regulation of HIPK1, HIPK2 and HIPK3 Protein Kinases by microRNAs
MicroRNA Models of Parkinson’s Disease with Special Emphasis on Drosophila melanogaster
CNS & Neurological Disorders - Drug Targets Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design